Efectos del telmisartán en el metabolismo de lípidos y glucosa: influencia en la prevención de enfermedades metabólicas y cardiovasculares

Introducción: el telmisartán es un antagonista selectivo de los receptores de angiotensina II tipo 1, utilizado principalmente para tratar la hipertensión arterial. Además de su efecto antihipertensivo, ha demostrado beneficios en el metabolismo de lípidos y glucosa, lo que le otorga un potencial te...

Full description

Autores:: Garces Barraza, Juan
Conde Cardona, Giancarlos
Contreras Puentes, Neyder
Osorio Peñaloza, Emily
Estremor Rodríguez, Rosemary
Zurita Gazabon, Karina
Villalba Torres, Karem
Tamayo Rivera, Susana

Tipo de recurso:: Article of journal

Fecha de publicación:: 2024

Institución:: Universidad de Cartagena

Repositorio:: Repositorio Universidad de Cartagena

Idioma:: spa

id	UCART2_b9713bf6632c9f4bb0e92aef5f662d3b
oai_identifier_str	oai:repositorio.unicartagena.edu.co:11227/19528
network_acronym_str	UCART2
network_name_str	Repositorio Universidad de Cartagena
repository_id_str
dc.title.spa.fl_str_mv	Efectos del telmisartán en el metabolismo de lípidos y glucosa: influencia en la prevención de enfermedades metabólicas y cardiovasculares
dc.title.translated.eng.fl_str_mv	Effects of telmisartan on lipid and glucose metabolism: influence on the prevention of metabolic and cardiovascular diseases
title	Efectos del telmisartán en el metabolismo de lípidos y glucosa: influencia en la prevención de enfermedades metabólicas y cardiovasculares
spellingShingle	Efectos del telmisartán en el metabolismo de lípidos y glucosa: influencia en la prevención de enfermedades metabólicas y cardiovasculares Telmisartan Apolipoprotein E PPARγ Lipid metabolism Glucose Telmisartán Apolipoproteína E PPARγ Metabolismo de lípidos Glucosa
title_short	Efectos del telmisartán en el metabolismo de lípidos y glucosa: influencia en la prevención de enfermedades metabólicas y cardiovasculares
title_full	Efectos del telmisartán en el metabolismo de lípidos y glucosa: influencia en la prevención de enfermedades metabólicas y cardiovasculares
title_fullStr	Efectos del telmisartán en el metabolismo de lípidos y glucosa: influencia en la prevención de enfermedades metabólicas y cardiovasculares
title_full_unstemmed	Efectos del telmisartán en el metabolismo de lípidos y glucosa: influencia en la prevención de enfermedades metabólicas y cardiovasculares
title_sort	Efectos del telmisartán en el metabolismo de lípidos y glucosa: influencia en la prevención de enfermedades metabólicas y cardiovasculares
dc.creator.fl_str_mv	Garces Barraza, Juan Conde Cardona, Giancarlos Contreras Puentes, Neyder Osorio Peñaloza, Emily Estremor Rodríguez, Rosemary Zurita Gazabon, Karina Villalba Torres, Karem Tamayo Rivera, Susana
dc.contributor.author.spa.fl_str_mv	Garces Barraza, Juan Conde Cardona, Giancarlos Contreras Puentes, Neyder Osorio Peñaloza, Emily Estremor Rodríguez, Rosemary Zurita Gazabon, Karina Villalba Torres, Karem Tamayo Rivera, Susana
dc.subject.eng.fl_str_mv	Telmisartan Apolipoprotein E PPARγ Lipid metabolism Glucose
topic	Telmisartan Apolipoprotein E PPARγ Lipid metabolism Glucose Telmisartán Apolipoproteína E PPARγ Metabolismo de lípidos Glucosa
dc.subject.spa.fl_str_mv	Telmisartán Apolipoproteína E PPARγ Metabolismo de lípidos Glucosa
description	Introducción: el telmisartán es un antagonista selectivo de los receptores de angiotensina II tipo 1, utilizado principalmente para tratar la hipertensión arterial. Además de su efecto antihipertensivo, ha demostrado beneficios en el metabolismo de lípidos y glucosa, lo que le otorga un potencial terapéutico en trastornos como el síndrome metabólico y la diabetes tipo 2. Objetivo: describir en detalle los efectos del telmisartán sobre el metabolismo de los lípidos y la glucosa, destacando su papel como modulador de los receptores PPARγ y su influencia en la apolipoproteína E. Métodos: se realizó una revisión narrativa de la literatura en bases de datos como PubMed y Science Direct. Se incluyeron estudios en inglés y español sobre la relación de telmisartán con el metabolismo de lípidos y glucosa. De los 42 artículos iniciales, 33 cumplieron los criterios de inclusión, excluyéndose aquellos con más de 15 años de antigüedad y duplicados. Resultados: telmisartán modula la expresión de apoE, promoviendo la eliminación de lípidos y reduciendo el riesgo de aterosclerosis. Además, su activación parcial de los receptores PPARγ mejora la oxidación de ácidos grasos y la sensibilidad a la insulina, previniendo la acumulación de grasa hepática. Estos efectos son esenciales para mejorar el perfil lipídico y glucémico en pacientes con dislipidemias y diabetes tipo 2. Conclusión: Telmisartán no solo controla la hipertensión, sino que también mejora el metabolismo de lípidos y glucosa, siendo una opción terapéutica valiosa en la prevención de enfermedades metabólicas y cardiovasculares.
publishDate	2024
dc.date.accessioned.none.fl_str_mv	2024-10-15T00:00:00Z 2025-05-23T10:00:30Z
dc.date.available.none.fl_str_mv	2024-10-15T00:00:00Z 2025-05-23T10:00:30Z
dc.date.issued.none.fl_str_mv	2024-10-15
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_dcae04bc
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.local.eng.fl_str_mv	Journal article
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/ARTREV
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	2215-7840
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/11227/19528
dc.identifier.doi.none.fl_str_mv	10.32997/rcb-2024-4897
dc.identifier.eissn.none.fl_str_mv	2389-7252
dc.identifier.url.none.fl_str_mv	https://doi.org/10.32997/rcb-2024-4897
identifier_str_mv	2215-7840 10.32997/rcb-2024-4897 2389-7252
url	https://hdl.handle.net/11227/19528 https://doi.org/10.32997/rcb-2024-4897
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Ciencias Biomédicas
dc.relation.bitstream.none.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/4897/4028
dc.relation.citationendpage.none.fl_str_mv	220
dc.relation.citationissue.spa.fl_str_mv	4
dc.relation.citationstartpage.none.fl_str_mv	210
dc.relation.citationvolume.spa.fl_str_mv	13
dc.relation.references.spa.fl_str_mv	Imenshahidi M, Roohbakhsh A, Hosseinzadeh H. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Vol. 171, Biomedicine and Pharmacotherapy. Elsevier Masson s.r.l.; 2024. Bhati SI, Haque SF, Siddiqi SS, Ahmad R. Effects of two different angiotensin receptor blockers on blood glucose level and HbA1c in type-2 diabetes mellitus patients with hypertension. Egypt J Intern Med. 2023 Oct 17;35(1). Lymperopoulos A, Borges JI, Stoicovy RA. RGS proteins and cardiovascular Angiotensin II Signaling: Novel opportunities for therapeutic targeting. Vol. 218, Biochemical Pharmacology. Elsevier Inc.; 2023. Yang C, Zhang Z, Liu J, Chen P, Li J, Shu H, et al. Research progress on multiple cell death pathways of podocytes in diabetic kidney disease. Vol. 29, Molecular Medicine. BioMed Central Ltd; 2023. Tian Y, Jing G, Zhang M. Insulin-degrading enzyme: Roles and pathways in ameliorating cognitive impairment associated with Alzheimer’s disease and diabetes. Vol. 90, Ageing Research Reviews. Elsevier Ireland Ltd; 2023. Wongcharoen W, Osataphan N, Gunaparn S, Srimahachota S, Porapakkham P, Dutsadeevettakul S, et al. Effect of renin angiotensin system inhibitors on long-term major cardiovascular outcomes in patients with high atherosclerotic cardiovascular risk. Sci Rep. 2023 Dec 1;13(1). Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Vol. 166, European Journal of Medicinal Chemistry. Elsevier Masson s.r.l.; 2019. p. 502–13. Wasta Esmail VA, Al-Nimer MSM, Mohammed MO. Effects of Orlistat or Telmisartan on the Serum Free Fatty Acids in Non-alcoholic Fatty Liver Disease Patients: An Open-Labeled Randomized Controlled Study. Turkish Journal of Gastroenterology. 2022 May 1;33(5):421–6. Abbas NAT, Fayed FA, El Sebaey RS, Hassan HA. Telmisartan and candesartan promote browning of white adipose tissue and reverse fatty liver changes in high fat diet fed male albino rats. Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr 1;397(4):2359–78. Huebbe P, Rimbach G. Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors. Vol. 37, Ageing Research Reviews. Elsevier Ireland Ltd; 2017. p. 146–61. Wu Y, Ma KL, Zhang Y, Wen Y, Wang GH, Hu ZB, et al. Lipid disorder and intrahepatic renin–angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease. Liver International. 2016 Oct 1;36(10):1525–34. Chan YK, Brar MS, Kirjavainen P V., Chen Y, Peng J, Li D, et al. High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with Lactobacillus rhamnosus GG (LGG) or telmisartan in ApoE-/- mice. BMC Microbiol. 2016 Nov 8;16(1):1–13. Miao M, Wang X, Liu T, Li YJ, Yu WQ, Yang TM, et al. Targeting PPARs for therapy of atherosclerosis: A review. Vol. 242, International Journal of Biological Macromolecules. Elsevier B.V.; 2023. Morsy MA, Abdel-Gaber SA, Rifaai RA, Mohammed MM, Nair AB, Abdelzaher WY. Protective mechanisms of telmisartan against hepatic ischemia/reperfusion injury in rats may involve PPARγ-induced TLR4/NF-κB suppression. Biomedicine and Pharmacotherapy. 2022 Jan 1;145. Qiu YY, Zhang J, Zeng FY, Zhu YZ. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Vol. 192, Pharmacological Research. Academic Press; 2023. Han X, Wu YL, Yang Q, Cao G. Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis. Vol. 222, Pharmacology and Therapeutics. Elsevier Inc.; 2021. Karmakar V, Gorain B. Potential molecular pathways of angiotensin receptor blockers in the brain toward cognitive improvement in dementia. Vol. 29, Drug Discovery Today. Elsevier Ltd; 2024. Hu W, Li Y, Zhao Y, Dong Y, Cui Y, Sun S, et al. Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype. Front Aging Neurosci. 2020 Jun 9;12. Aboelez MO, Ezelarab HAA, Alotaibi G, Abouzed DEE. Inflammatory setting, therapeutic strategies targeting some pro-inflammatory cytokines and pathways in mitigating ischemia/reperfusion-induced hepatic injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol [Internet]. 2024 Apr 21; Available from: https://link.springer.com/10.1007/s00210-024-03074-y Abdelhamid AM, Elsheakh AR, Suddek GM, Abdelaziz RR. Telmisartan alleviates alcohol-induced liver injury by activation of PPAR-γ/ Nrf-2 crosstalk in mice. Int Immunopharmacol. 2021 Oct 1;99. Quan W, Xu CS, Li XC, Yang C, Lan T, Wang MY, et al. Telmisartan inhibits microglia-induced neurotoxic A1 astrocyte conversion via PPARγ-mediated NF-κB/p65 degradation. Int Immunopharmacol. 2023 Oct 1;123. Liu Y, Wang J, Luo S, Zhan Y, Lu Q. The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review. Vol. 113, Journal of Autoimmunity. Academic Press; 2020. Xiao Q, He J, Lei A, Xu H, Zhang L, Zhou P, et al. PPARγ enhances ILC2 function during allergic airway inflammation via transcription regulation of ST2. Mucosal Immunol. 2021 Mar 1;14(2):468–78. Li Y, Pan Y, Zhao X, Wu S, Li F, Wang Y, et al. Peroxisome proliferator-activated receptors: A key link between lipid metabolism and cancer progression. Vol. 43, Clinical Nutrition. Churchill Livingstone; 2024. p. 332–45. Iwane S, Nemoto W, Miyamoto T, Hayashi T, Tanaka M, Uchitani K, et al. Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy. Sci Rep. 2024 Dec 1;14(1). Abdel Rasheed NO, Ibrahim WW. Telmisartan neuroprotective effects in 3-nitropropionic acid Huntington’s disease model in rats: Cross talk between PPAR-γ and PI3K/Akt/GSK-3β pathway. Life Sci. 2022 May 15;297. Singh TP, Moxon J V., Gasser TC, Dalman RL, Bourke M, Bourke B, et al. Effect of Telmisartan on the Peak Wall Stress and Peak Wall Rupture Index of Small Abdominal Aortic Aneurysms: An Exploratory Analysis of the TEDY Trial. European Journal of Vascular and Endovascular Surgery. 2022 Oct 1;64(4):396–404. Golledge J, Pinchbeck J, Tomee SM, Rowbotham SE, Singh TP, Moxon J V., et al. Efficacy of Telmisartan to Slow Growth of Small Abdominal Aortic Aneurysms: A Randomized Clinical Trial. JAMA Cardiol. 2020 Dec 1;5(12):1374–81. Lu TL, Wu SN. Investigating the Impact of Selective Modulators on the Renin–Angiotensin–Aldosterone System: Unraveling Their Off-Target Perturbations of Transmembrane Ionic Currents. Vol. 24, International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI); 2023. Pushpakom S, Kolamunnage-Dona R, Taylor C, Foster T, Spowart C, García-Fiñana M, et al. TAILoR (TelmisArtan and insulin resistance in human immunodeficiency virus [hiv]): An adaptive-design, dose-ranging phase iib randomized trial of telmisartan for the reduction of insulin resistance in hiv-positive individuals on combination antiretroviral therapy. Clinical Infectious Diseases. 2020 May 6;70(10):2062–72. Petrov MS. The Pharmacological Landscape for Fatty Change of the Pancreas. Drugs. 2024; Xiao S, Qi M, Zhou Q, Gong H, Wei D, Wang G, et al. Macrophage fatty acid oxidation in atherosclerosis. Vol. 170, Biomedicine and Pharmacotherapy. Elsevier Masson s.r.l.; 2024. Zheng L, Zhao Z, Lin J, Li H, Wu G, Qi X, et al. Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction. Eur J Pharmacol. 2022 Jan 15;915.
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-nd/4.0
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	https://creativecommons.org/licenses/by-nc-nd/4.0 http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Universidad de Cartagena
dc.source.spa.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/4897
institution	Universidad de Cartagena
bitstream.url.fl_str_mv	https://repositorio.unicartagena.edu.co/bitstreams/58583f5f-f0ca-4e15-8375-f998e3824ed8/download
bitstream.checksum.fl_str_mv	8e4ed9bc8aa6424fc87d2fca208bc439
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Biblioteca Digital Universidad de Cartagena
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1834111407720759296
spelling	Garces Barraza, JuanConde Cardona, GiancarlosContreras Puentes, NeyderOsorio Peñaloza, EmilyEstremor Rodríguez, RosemaryZurita Gazabon, KarinaVillalba Torres, KaremTamayo Rivera, Susana2024-10-15T00:00:00Z2025-05-23T10:00:30Z2024-10-15T00:00:00Z2025-05-23T10:00:30Z2024-10-152215-7840https://hdl.handle.net/11227/1952810.32997/rcb-2024-48972389-7252https://doi.org/10.32997/rcb-2024-4897Introducción: el telmisartán es un antagonista selectivo de los receptores de angiotensina II tipo 1, utilizado principalmente para tratar la hipertensión arterial. Además de su efecto antihipertensivo, ha demostrado beneficios en el metabolismo de lípidos y glucosa, lo que le otorga un potencial terapéutico en trastornos como el síndrome metabólico y la diabetes tipo 2. Objetivo: describir en detalle los efectos del telmisartán sobre el metabolismo de los lípidos y la glucosa, destacando su papel como modulador de los receptores PPARγ y su influencia en la apolipoproteína E. Métodos: se realizó una revisión narrativa de la literatura en bases de datos como PubMed y Science Direct. Se incluyeron estudios en inglés y español sobre la relación de telmisartán con el metabolismo de lípidos y glucosa. De los 42 artículos iniciales, 33 cumplieron los criterios de inclusión, excluyéndose aquellos con más de 15 años de antigüedad y duplicados. Resultados: telmisartán modula la expresión de apoE, promoviendo la eliminación de lípidos y reduciendo el riesgo de aterosclerosis. Además, su activación parcial de los receptores PPARγ mejora la oxidación de ácidos grasos y la sensibilidad a la insulina, previniendo la acumulación de grasa hepática. Estos efectos son esenciales para mejorar el perfil lipídico y glucémico en pacientes con dislipidemias y diabetes tipo 2. Conclusión: Telmisartán no solo controla la hipertensión, sino que también mejora el metabolismo de lípidos y glucosa, siendo una opción terapéutica valiosa en la prevención de enfermedades metabólicas y cardiovasculares.Introduction: telmisartan is a selective angiotensin II type 1 receptor antagonist, primarily used to treat arterial hypertension. In addition to its antihypertensive effects, it has shown benefits in lipid and glucose metabolism, giving it therapeutic potential in conditions such as metabolic syndrome and type 2 diabetes. Objective: To describe in detail the effects of telmisartan on lipid and glucose metabolism, highlighting its role as a modulator of PPARγ receptors and its influence on apolipoprotein E. Methods: a narrative literature review was conducted using databases such as PubMed and Science Direct. Studies in English and Spanish addressing the relationship of telmisartan with lipid and glucose metabolism were included. Of the initial 42 articles, 33 met the inclusion criteria, excluding those older than 15 years and duplicates. Results: telmisartan modulates apoE expression, promoting lipid clearance and reducing the risk of atherosclerosis. Additionally, its partial activation of PPARγ receptors enhances fatty acid oxidation and insulin sensitivity, preventing hepatic fat accumulation. These effects are crucial in improving lipid and glycemic profiles in patients with dyslipidemia and type 2 diabetes. Conclusions: telmisartan not only controls hypertension but also improves lipid and glucose metabolism, making it a valuable therapeutic option for the prevention of metabolic and cardiovascular diseases.application/pdfspaUniversidad de CartagenaRevista Ciencias Biomédicashttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/4897/4028220421013Imenshahidi M, Roohbakhsh A, Hosseinzadeh H. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Vol. 171, Biomedicine and Pharmacotherapy. Elsevier Masson s.r.l.; 2024.Bhati SI, Haque SF, Siddiqi SS, Ahmad R. Effects of two different angiotensin receptor blockers on blood glucose level and HbA1c in type-2 diabetes mellitus patients with hypertension. Egypt J Intern Med. 2023 Oct 17;35(1).Lymperopoulos A, Borges JI, Stoicovy RA. RGS proteins and cardiovascular Angiotensin II Signaling: Novel opportunities for therapeutic targeting. Vol. 218, Biochemical Pharmacology. Elsevier Inc.; 2023.Yang C, Zhang Z, Liu J, Chen P, Li J, Shu H, et al. Research progress on multiple cell death pathways of podocytes in diabetic kidney disease. Vol. 29, Molecular Medicine. BioMed Central Ltd; 2023.Tian Y, Jing G, Zhang M. Insulin-degrading enzyme: Roles and pathways in ameliorating cognitive impairment associated with Alzheimer’s disease and diabetes. Vol. 90, Ageing Research Reviews. Elsevier Ireland Ltd; 2023.Wongcharoen W, Osataphan N, Gunaparn S, Srimahachota S, Porapakkham P, Dutsadeevettakul S, et al. Effect of renin angiotensin system inhibitors on long-term major cardiovascular outcomes in patients with high atherosclerotic cardiovascular risk. Sci Rep. 2023 Dec 1;13(1).Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Vol. 166, European Journal of Medicinal Chemistry. Elsevier Masson s.r.l.; 2019. p. 502–13.Wasta Esmail VA, Al-Nimer MSM, Mohammed MO. Effects of Orlistat or Telmisartan on the Serum Free Fatty Acids in Non-alcoholic Fatty Liver Disease Patients: An Open-Labeled Randomized Controlled Study. Turkish Journal of Gastroenterology. 2022 May 1;33(5):421–6.Abbas NAT, Fayed FA, El Sebaey RS, Hassan HA. Telmisartan and candesartan promote browning of white adipose tissue and reverse fatty liver changes in high fat diet fed male albino rats. Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr 1;397(4):2359–78.Huebbe P, Rimbach G. Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors. Vol. 37, Ageing Research Reviews. Elsevier Ireland Ltd; 2017. p. 146–61.Wu Y, Ma KL, Zhang Y, Wen Y, Wang GH, Hu ZB, et al. Lipid disorder and intrahepatic renin–angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease. Liver International. 2016 Oct 1;36(10):1525–34.Chan YK, Brar MS, Kirjavainen P V., Chen Y, Peng J, Li D, et al. High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with Lactobacillus rhamnosus GG (LGG) or telmisartan in ApoE-/- mice. BMC Microbiol. 2016 Nov 8;16(1):1–13.Miao M, Wang X, Liu T, Li YJ, Yu WQ, Yang TM, et al. Targeting PPARs for therapy of atherosclerosis: A review. Vol. 242, International Journal of Biological Macromolecules. Elsevier B.V.; 2023.Morsy MA, Abdel-Gaber SA, Rifaai RA, Mohammed MM, Nair AB, Abdelzaher WY. Protective mechanisms of telmisartan against hepatic ischemia/reperfusion injury in rats may involve PPARγ-induced TLR4/NF-κB suppression. Biomedicine and Pharmacotherapy. 2022 Jan 1;145.Qiu YY, Zhang J, Zeng FY, Zhu YZ. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Vol. 192, Pharmacological Research. Academic Press; 2023.Han X, Wu YL, Yang Q, Cao G. Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis. Vol. 222, Pharmacology and Therapeutics. Elsevier Inc.; 2021.Karmakar V, Gorain B. Potential molecular pathways of angiotensin receptor blockers in the brain toward cognitive improvement in dementia. Vol. 29, Drug Discovery Today. Elsevier Ltd; 2024.Hu W, Li Y, Zhao Y, Dong Y, Cui Y, Sun S, et al. Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype. Front Aging Neurosci. 2020 Jun 9;12.Aboelez MO, Ezelarab HAA, Alotaibi G, Abouzed DEE. Inflammatory setting, therapeutic strategies targeting some pro-inflammatory cytokines and pathways in mitigating ischemia/reperfusion-induced hepatic injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol [Internet]. 2024 Apr 21; Available from: https://link.springer.com/10.1007/s00210-024-03074-yAbdelhamid AM, Elsheakh AR, Suddek GM, Abdelaziz RR. Telmisartan alleviates alcohol-induced liver injury by activation of PPAR-γ/ Nrf-2 crosstalk in mice. Int Immunopharmacol. 2021 Oct 1;99.Quan W, Xu CS, Li XC, Yang C, Lan T, Wang MY, et al. Telmisartan inhibits microglia-induced neurotoxic A1 astrocyte conversion via PPARγ-mediated NF-κB/p65 degradation. Int Immunopharmacol. 2023 Oct 1;123.Liu Y, Wang J, Luo S, Zhan Y, Lu Q. The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review. Vol. 113, Journal of Autoimmunity. Academic Press; 2020.Xiao Q, He J, Lei A, Xu H, Zhang L, Zhou P, et al. PPARγ enhances ILC2 function during allergic airway inflammation via transcription regulation of ST2. Mucosal Immunol. 2021 Mar 1;14(2):468–78.Li Y, Pan Y, Zhao X, Wu S, Li F, Wang Y, et al. Peroxisome proliferator-activated receptors: A key link between lipid metabolism and cancer progression. Vol. 43, Clinical Nutrition. Churchill Livingstone; 2024. p. 332–45.Iwane S, Nemoto W, Miyamoto T, Hayashi T, Tanaka M, Uchitani K, et al. Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy. Sci Rep. 2024 Dec 1;14(1).Abdel Rasheed NO, Ibrahim WW. Telmisartan neuroprotective effects in 3-nitropropionic acid Huntington’s disease model in rats: Cross talk between PPAR-γ and PI3K/Akt/GSK-3β pathway. Life Sci. 2022 May 15;297.Singh TP, Moxon J V., Gasser TC, Dalman RL, Bourke M, Bourke B, et al. Effect of Telmisartan on the Peak Wall Stress and Peak Wall Rupture Index of Small Abdominal Aortic Aneurysms: An Exploratory Analysis of the TEDY Trial. European Journal of Vascular and Endovascular Surgery. 2022 Oct 1;64(4):396–404.Golledge J, Pinchbeck J, Tomee SM, Rowbotham SE, Singh TP, Moxon J V., et al. Efficacy of Telmisartan to Slow Growth of Small Abdominal Aortic Aneurysms: A Randomized Clinical Trial. JAMA Cardiol. 2020 Dec 1;5(12):1374–81.Lu TL, Wu SN. Investigating the Impact of Selective Modulators on the Renin–Angiotensin–Aldosterone System: Unraveling Their Off-Target Perturbations of Transmembrane Ionic Currents. Vol. 24, International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI); 2023.Pushpakom S, Kolamunnage-Dona R, Taylor C, Foster T, Spowart C, García-Fiñana M, et al. TAILoR (TelmisArtan and insulin resistance in human immunodeficiency virus [hiv]): An adaptive-design, dose-ranging phase iib randomized trial of telmisartan for the reduction of insulin resistance in hiv-positive individuals on combination antiretroviral therapy. Clinical Infectious Diseases. 2020 May 6;70(10):2062–72.Petrov MS. The Pharmacological Landscape for Fatty Change of the Pancreas. Drugs. 2024;Xiao S, Qi M, Zhou Q, Gong H, Wei D, Wang G, et al. Macrophage fatty acid oxidation in atherosclerosis. Vol. 170, Biomedicine and Pharmacotherapy. Elsevier Masson s.r.l.; 2024.Zheng L, Zhao Z, Lin J, Li H, Wu G, Qi X, et al. Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction. Eur J Pharmacol. 2022 Jan 15;915.Juan Garces Barraza, Giancarlos Conde Cardona, Neyder Contreras Puentes, Emily Osorio Peñaloza, Rosemary Estremor Rodríguez, Karina Zurita Gazabon, Karem Villalba Torres, Susana Tamayo Rivera - 2024https://creativecommons.org/licenses/by-nc-nd/4.0http://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/4897TelmisartanApolipoprotein EPPARγLipid metabolismGlucoseTelmisartánApolipoproteína EPPARγMetabolismo de lípidosGlucosaEfectos del telmisartán en el metabolismo de lípidos y glucosa: influencia en la prevención de enfermedades metabólicas y cardiovascularesEffects of telmisartan on lipid and glucose metabolism: influence on the prevention of metabolic and cardiovascular diseasesArtículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articleJournal articlehttp://purl.org/redcol/resource_type/ARTREVPublicationOREORE.xmltext/xml3057https://repositorio.unicartagena.edu.co/bitstreams/58583f5f-f0ca-4e15-8375-f998e3824ed8/download8e4ed9bc8aa6424fc87d2fca208bc439MD5111227/19528oai:repositorio.unicartagena.edu.co:11227/195282025-05-23 05:00:30.489https://creativecommons.org/licenses/by-nc-nd/4.0Juan Garces Barraza, Giancarlos Conde Cardona, Neyder Contreras Puentes, Emily Osorio Peñaloza, Rosemary Estremor Rodríguez, Karina Zurita Gazabon, Karem Villalba Torres, Susana Tamayo Rivera - 2024metadata.onlyhttps://repositorio.unicartagena.edu.coBiblioteca Digital Universidad de Cartagenabdigital@metabiblioteca.com

Efectos del telmisartán en el metabolismo de lípidos y glucosa: influencia en la prevención de enfermedades metabólicas y cardiovasculares

Publicaciones similares